Skip to main content

Table 2 Cyclin D1 and Ki67 immunolabelling in the histological variants of Thyroid neoplasm

From: Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules

  Percentage of Cyclin D1 Percentage of Ki67
Variants of Thyroid neoplasm Immunolabelled tumor cells (%) Immunolabelled tumor cells (%)
MSR Mean ± SD PPV MSR Mean ± SD PPV
(Range) (Range)
Papillary thyroid carcinoma (n = 59) 48.5 42.9 ± 19.1 91.5 3.5 5.2 ± 5.7 76.3
(6.1–76.7) (0.2–37.4)
Medullary thyroid carcinoma (n = 1) 66.4 66.4 100 4 4 11.1
Follicular carcinoma (n = 9) 34.2 36.0 ± 26.6 77.8 2.4 4.5 ± 6.1 28.6
(5.8–76) (0.9–20.3)
Poorly differentiated thyroid carcinoma (n = 7) 45.9 42.3 ± 21 85.7 4.1 5.4 ± 4.2 60
(2.8–68.1) (0.3–12.2)
Well differentiated tumor-uncertain malignant potential (n = 2) 41.5 41.5 ± 3.2 100 3.15 3.2 ± 2.9 50
(39.2–43.7) (1.1–5.2)
Follicular adenoma (n = 7) 13.1 17.5 ± 15.3 66.7 2.3 2.9 ± 1.9 20
(2.5–43.2) (1–6.8)
Anaplastic thyroid carcinoma (n = 5) 9.9 17.2 ± 19.5 33.3 10.4 8.3 ± 3.5 66.7
(1.9–49.7) (4.4–11.7)
Background (inflammation or adenomatous goiter, n = 12) 3.4 3.4 ± 0.9   3.05 3.7 ± 1.4  
(2.1–5.2) (2.1–7.2)
  1. *MSR Medisan stain ratio, PPV Positive predictive value